Recent Advances of Bioresponsive Polymeric Nanomedicine for Cancer Therapy

Overview

Journal Nano Res

Date 2022 Nov 21

PMID 36405982

Authors

Tu Hong

Xinyuan Shen

Madiha Zahra Syeda

Yang Zhang

Haonan Sheng

Yipeng Zhou

Jinming Xu

Chaojie Zhu

Hongjun Li

Zhen Gu

Longguang Tang

Affiliations

Soon will be listed here.

Abstract

A bioresponsive polymeric nanocarrier for drug delivery is able to alter its physical and physicochemical properties in response to a variety of biological signals and pathological changes, and can exert its therapeutic efficacy within a confined space. These nanosystems can optimize the biodistribution and subcellular location of therapeutics by exploiting the differences in biochemical properties between tumors and normal tissues. Moreover, bioresponsive polymer-based nanosystems could be rationally designed as precision therapeutic platforms by optimizing the combination of responsive elements and therapeutic components according to the patient-specific disease type and stage. In this review, recent advances in smart bioresponsive polymeric nanosystems for cancer chemotherapy and immunotherapy will be summarized. We mainly discuss three categories, including acidity-sensitive, redox-responsive, and enzyme-triggered polymeric nanosystems. The important issues regarding clinical translation such as reproducibility, manufacture, and probable toxicity, are also commented.

Citing Articles

Circular RNA circAGAP1 promotes sunitinib sensitivity in renal cell carcinoma via sponging multiple PDGFR-targeted miRNAs.

Lv Q, Wang G, Hong Y, Zhu T, Qin S, Sun S Oncol Res. 2025; 33(2):407-420.

PMID: 39866227 PMC: 11754003. DOI: 10.32604/or.2024.047698.

Oxaliplatin-Loaded Mil-100(Fe) for Chemotherapy-Ferroptosis Combined Therapy for Gastric Cancer.

Sun B, Zheng X, Zhang X, Zhang H, Jiang Y ACS Omega. 2024; 9(14):16676-16686.

PMID: 38617668 PMC: 11007804. DOI: 10.1021/acsomega.4c00658.

Recent Advances in Nanomedicine for Ocular Fundus Neovascularization Disease Management.

Zhou Y, Xu M, Shen W, Xu Y, Shao A, Xu P Adv Healthc Mater. 2024; 13(17):e2304626.

PMID: 38406994 PMC: 11468720. DOI: 10.1002/adhm.202304626.

Red blood cell-derived materials for cancer therapy: Construction, distribution, and applications.

Ding J, Ding X, Liao W, Lu Z Mater Today Bio. 2024; 24:100913.

PMID: 38188647 PMC: 10767221. DOI: 10.1016/j.mtbio.2023.100913.

Current research trends of nanomedicines.

Liu Q, Zou J, Chen Z, He W, Wu W Acta Pharm Sin B. 2023; 13(11):4391-4416.

PMID: 37969727 PMC: 10638504. DOI: 10.1016/j.apsb.2023.05.018.

References

Lao Y, Phua K, Leong K . Aptamer nanomedicine for cancer therapeutics: barriers and potential for translation. ACS Nano. 2015; 9(3):2235-54. DOI: 10.1021/nn507494p. View

He H, Sun L, Ye J, Liu E, Chen S, Liang Q . Enzyme-triggered, cell penetrating peptide-mediated delivery of anti-tumor agents. J Control Release. 2015; 240:67-76. DOI: 10.1016/j.jconrel.2015.10.040. View

Waite C, Roth C . Nanoscale drug delivery systems for enhanced drug penetration into solid tumors: current progress and opportunities. Crit Rev Biomed Eng. 2012; 40(1):21-41. PMC: 3639314. DOI: 10.1615/critrevbiomedeng.v40.i1.20. View

Boedtkjer E, Pedersen S . The Acidic Tumor Microenvironment as a Driver of Cancer. Annu Rev Physiol. 2019; 82:103-126. DOI: 10.1146/annurev-physiol-021119-034627. View

Jia X, He J, Shen L, Chen J, Wei Z, Qin X . Gradient Redox-Responsive and Two-Stage Rocket-Mimetic Drug Delivery System for Improved Tumor Accumulation and Safe Chemotherapy. Nano Lett. 2019; 19(12):8690-8700. DOI: 10.1021/acs.nanolett.9b03340. View

Yuan Y, Liu J, Liu B . Conjugated-polyelectrolyte-based polyprodrug: targeted and image-guided photodynamic and chemotherapy with on-demand drug release upon irradiation with a single light source. Angew Chem Int Ed Engl. 2014; 53(28):7163-8. DOI: 10.1002/anie.201402189. View

Chen B, Yan Y, Yang Y, Cao G, Wang X, Wang Y . A pyroptosis nanotuner for cancer therapy. Nat Nanotechnol. 2022; 17(7):788-798. DOI: 10.1038/s41565-022-01125-0. View

Crucho C . Stimuli-responsive polymeric nanoparticles for nanomedicine. ChemMedChem. 2014; 10(1):24-38. DOI: 10.1002/cmdc.201402290. View

Wallace A, Kapoor V, Sun J, Mrass P, Weninger W, Heitjan D . Transforming growth factor-beta receptor blockade augments the effectiveness of adoptive T-cell therapy of established solid cancers. Clin Cancer Res. 2008; 14(12):3966-74. PMC: 2491721. DOI: 10.1158/1078-0432.CCR-08-0356. View

10.

Longley D, Johnston P . Molecular mechanisms of drug resistance. J Pathol. 2005; 205(2):275-92. DOI: 10.1002/path.1706. View

11.

Li H, Du J, Liu J, Du X, Shen S, Zhu Y . Smart Superstructures with Ultrahigh pH-Sensitivity for Targeting Acidic Tumor Microenvironment: Instantaneous Size Switching and Improved Tumor Penetration. ACS Nano. 2016; 10(7):6753-61. DOI: 10.1021/acsnano.6b02326. View

12.

Tan R, Lee C, Pichika M, Cheng S, Lam K . PH Responsive Polyurethane for the Advancement of Biomedical and Drug Delivery. Polymers (Basel). 2022; 14(9). PMC: 9102459. DOI: 10.3390/polym14091672. View

13.

Shim M, Xia Y . A reactive oxygen species (ROS)-responsive polymer for safe, efficient, and targeted gene delivery in cancer cells. Angew Chem Int Ed Engl. 2013; 52(27):6926-9. PMC: 3746021. DOI: 10.1002/anie.201209633. View

14.

Sun T, Zhang Y, Pang B, Hyun D, Yang M, Xia Y . Engineered nanoparticles for drug delivery in cancer therapy. Angew Chem Int Ed Engl. 2014; 53(46):12320-64. DOI: 10.1002/anie.201403036. View

15.

Blanco E, Shen H, Ferrari M . Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nat Biotechnol. 2015; 33(9):941-51. PMC: 4978509. DOI: 10.1038/nbt.3330. View

16.

An X, Zhu A, Luo H, Ke H, Chen H, Zhao Y . Rational Design of Multi-Stimuli-Responsive Nanoparticles for Precise Cancer Therapy. ACS Nano. 2016; 10(6):5947-58. DOI: 10.1021/acsnano.6b01296. View

17.

Conlon K, Lugli E, Welles H, Rosenberg S, Tito Fojo A, Morris J . Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer. J Clin Oncol. 2014; 33(1):74-82. PMC: 4268254. DOI: 10.1200/JCO.2014.57.3329. View

18.

Mo R, Jiang T, DiSanto R, Tai W, Gu Z . ATP-triggered anticancer drug delivery. Nat Commun. 2014; 5:3364. DOI: 10.1038/ncomms4364. View

19.

Marusyk A, Polyak K . Tumor heterogeneity: causes and consequences. Biochim Biophys Acta. 2009; 1805(1):105-17. PMC: 2814927. DOI: 10.1016/j.bbcan.2009.11.002. View

20.

Dreher M, Liu W, Michelich C, Dewhirst M, Yuan F, Chilkoti A . Tumor vascular permeability, accumulation, and penetration of macromolecular drug carriers. J Natl Cancer Inst. 2006; 98(5):335-44. DOI: 10.1093/jnci/djj070. View